详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Synergistic effect of canakinumab with epidermal growth factor receptor tyrosine kinase inhibitors versus with chemotherapy for non-small cell lung cancer

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China. [3]West China School of Nursing, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： Canakinumab interleukin-1β (IL-1β) non-small cell lung cancer (NSCLC) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学 3 区呼吸系统

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学 3 区呼吸系统

第一作者：

第一作者机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China. [*1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China [*2]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis [2]Characteristics of pro- and anti-inflammatory cytokines alteration in PTSD patients exposed to a deadly earthquake. [3]TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) [4]Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC) [5]Evaluation of Toxicity Profile of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC) [6]Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo [7]Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters [8]A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) [9]A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [10]Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)